Acute myeloid leukemia

The FDA ( U.S. Food and Drug Administration ) has provided full approval to Venclexta ( Venetoclax ) in...


Venetoclax ( Venclexta ) in newly-diagnosed AML patients who are ineligible for intensive chemotherapy is supported by data from a...


The FDA ( U.S. Food and Drug Administration ) has approved Onureg ( Azacitidine 300 mg tablets, CC-486 ) for...


JNJ-68284528 ( JNJ-4528 ) is a chimeric antigen receptor T ( CAR-T ) cell therapy containing 2 B-cell maturation antigen...


Current available therapies for patients with acute myeloid leukemia ( AML ) who are ineligible for intensive therapy yield limited...


The European Commission ( EC ) has approved the oral once-daily therapy Xospata ( Gilteritinib ) as a monotherapy for...


The results from the phase 3 ADMIRAL clinical trial comparing Gilteritinib ( Xospata ) to salvage chemotherapy in adult patients...


Patients assigned to Gilteritinib ( Xospata ) were found to have a 36% reduction in risk of death compared with...


Acute myeloid leukemia ( AML ) remains a highly resistant disease to conventional chemotherapy, with a median survival of only...


The FDA ( U.S. Food and Drug Administration ) has approved Tibsovo ( Ivosidenib ) tablets for the treatment of...


The FDA ( U.S. Food and Drug Administration ) has approved Xospata ( Gilteritinib ) tablets for the treatment of...


Aging is associated with an increased incidence of cancer and cardiovascular disease. Researchers recently used whole-exome sequencing data to identify...


On August 1, 2017, the FDA ( U.S. Food and Drug Administration ) has granted regular approval to Idhifa (...


Results from the phase II study of WT1 first-in-class immunotherapeutic anti-cancer treatment in multiple myeloma patients following autologous stem cell...


The FDA ( Food and Drug Administration ) has granted Breakthrough Therapy designation to PKC412 ( Midostaurin ). Midostaurin is...


Ther FDA ( Food and Drug Administration ) has granted accelerated approval to Rucaparib ( Rubraca ) for treatment of...


Positive results from the global phase III RATIFY ( CALGB 10603 ) clinical trial were announced. In the study, adult...


Mutations in the ALK gene were identified in the tumors of two leukemia patients, and laboratory studies indicated that leukemias...


Results from a phase II study, published in the American Society of Hematology journal Blood, showed patients with previously untreated...


Treatment outcomes for older patients with acute myeloid leukemia ( AML ) have remained dismal. A randomized, phase 2 trial...